Clinical Trials Logo

Clinical Trial Summary

The blood concentration of the protein RANKL could be predictive of the calcification of the leg arteries, which is a major complication occurring during diabetes. The objective of the DIACART study is to show that blood RANKL concentration predict the progression of calcification of the leg arteries in diabetic patients, independently of other cardiovascular risk factors.


Clinical Trial Description

Introduction: Peripheral arterial disease (PAD) is the primary major amputation risk factor in diabetes. The PAD is particularly common among diabetic patients at high cardiovascular risk (20-30% of coronary patients have PAD). The calcification of atherosclerotic plaque and media leg arteries contributes to narrowing of the arterial lumen and exposes the diabetic patient to critical limb ischemia. The receptor RANK (Receptor Activator for Nuclear Factor κ B) and its ligand RANKL form a complex which initially was described as being involved in bone metabolism by activating osteoclasts but the RANK / RANKLigand system could also be involved in the process calcification and arterial obstruction, especially in the lower limbs. Currently there is anti-RANKL antibody used in humans that could possibly slow down this process. But it is necessary to prove the involvement of this system in PAD in diabetic patients at high cardiovascular risk before proposing a therapeutic trial.

Assumptions: the concentration of RANKL could be predictive of calcification of leg arteries in diabetes Main objective: To show that serum RANKL concentrations predict the progression of calcification of the leg arteries in diabetic patients, independently of other cardiovascular risk factors.

Secondary Objectives:

- To show the link between other proteins of bone remodeling, markers of inflammation and glycation, and calcification of leg arteries.

- Measuring the rate of calcification leg arteries.

- Phenotype diabetic patients who have the highest rate of calcification. Primary Outcome: Predictive power of serum RANKL concentration at T0 on the progression of calcification of leg arteries between T0 and T24 months.

Methodology: prospective observational study. The calcium score of leg arteries will be evaluated by a scanner at T0 and 24 months.

Inclusion criteria:

- type 2 diabetes

- women over 60

- men over 50 years

- men and women with known coronary artery disease Non-inclusion criteria:

- severe renal failure

- immunodeficiency

- acute infectious or inflammatory disease

- history of bypass surgery or sub-popliteal angioplasty Number of subjects required: 188 patients will be included. Total study duration: 24 months Inclusion period: 24 months ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02431234
Study type Observational
Source Assistance Publique - Hôpitaux de Paris
Contact
Status Active, not recruiting
Phase
Start date February 2014
Completion date September 2018

See also
  Status Clinical Trial Phase
Completed NCT00823849 - Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker Phase 4
Recruiting NCT00912756 - Sufficient Treatment of Peripheral Intervention by Cilostazol Phase 4
Completed NCT00712946 - Preoperative Heart Rate Variability and Baroreflex Sensitivity in ASO Patients During Various Sleep Stages N/A
Enrolling by invitation NCT02864654 - Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia Phase 1/Phase 2
Completed NCT05083299 - Multicenter, Therapeutic Use Observational Study to Evaluate the Effects of Concurrent Therapy of Sarpogrelate
Completed NCT01518205 - HELP-Apheresis in Diabetic Ischemic Foot Treatment (H.A.D.I.F) N/A
Recruiting NCT02877173 - A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans Phase 2
Recruiting NCT00145262 - TACT-NAGOYA: Therapeutic Angiogenesis Using Cell Transplantation Phase 2